Conference Reports for NATAP

Back

The International Liver Congress™ EASL - European Association for the Study of the Liver June 21-24 2023     A gene editing approach for chronic hepatitis B: elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease - (07/11/23)   Non-alcoholic fatty liver disease awareness, misperception, and their association with healthcare access in Korean general population: a nationally representative survey - (07/11/23)   Non-alcoholic steatohepatitis disease progression in participants from the United States TARGET-NASH real world longitudinal observational study - (07/10/23)   HCV and HBV prevalence and associated risk factors among people who inject drugs in Kenya - (07/05/23)   Improving hepatitis B screening and linkage to care rates via the electronic medical record, provider engagement, and patient navigation in a large, urban health system - (07/05/23)   Tenofovir prophylaxis during pregnancy for the elimination of mother-to-child transmission of hepatitis B virus: A cost-effectiveness analysis - (07/05/23)   Estimating the Prevalence of Hepatitis Delta Infection among Foreign-Born Adults with Chronic Hepatitis B in the United States - (07/05/23)   Impact of the anti-HDV reflex testing on the reduction of hepatitis D burden in Spain - (07/05/23)   Low coverage of hepatitis D virus testing in individuals with HIV and HBV in the Netherlands (ATHENA): a retrospective, cross-sectional and longitudinal study - (07/05/23)   Prevalence (15%) and incidence of delta hepatitis in HIV-HBV coinfected patients in the Dat'AIDS (French) cohort - (07/05/23)   An international coalition to eliminate hepatitis B virus (ICE-HBV) survey confirms inadequate HBV/HDV screening and diagnosis diminishing elimination targets in resource limited settings - (07/05/23)   Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease - (07/05/23)   Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D - (07/05/23)   SAFE Score Rates Liver Disease Risk Well in US General Population - Who is SAFE from chronic liver disease? A population-based approach for early detection in the US. - Mark Mascolini (07/05/23)   Significant dose-dependent reduction in liver stiffness using transient elastography in a phase 3 randomized placebo-controlled trial of obeticholic acid over 48 months in patients with pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis - (07/05/23)   A global research priority agenda to advance public health responses to fatty liver disease - (07/05/23)   Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial - (07/05/23)   Use of antidiabetic and lipid-lowering medications associated with lower scores of liver fibrosis biomarkers in non-alcoholic steatohepatitis (NASH) patients - (07/05/23)   Effectiveness of a direct care action strategy at the drug addiction center (test and treat in point of care) for the detection and treatment of hepatitis C in drug users on opioid agonist substitution therapy - (07/05/23)   Finding undiagnosed hepatitis C cases: using machine learning to identify clinical attributes and social determinants of health to improve the screening-to-diagnosis ratio and improve efficiency and linkage to care - (07/05/23)   Est. 1.7 Milllion HCV+ in EU/EEA Estimation of prevalence of chronic HCV infection in EU/EEA countries using multiparameter evidence synthesis - (07/05/23)   Improving hepatitis B screening and linkage to care rates via the electronic medical record, provider engagement, and patient navigation in a large, urban health system - (07/04/23)   Identification of Liver-associated Gene Signatures from Serum Exosomes in Patients with Chronic Hepatitis B - (07/04/23)   The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: Interim results from a Phase 1 study in healthy volunteers - (07/04/23)   Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: Findings from a Phase 2, randomized open-label study in China - (07/04/23)   Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International Network (HDIN) - (07/03/23)   Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target WED-114 coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors - (07/03/23)   Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: Preliminary results from a randomized, blinded, Phase 1b study - (07/03/23)   Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target WED-114 coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors - (07/03/23)   A Novel Class of Orally Available Small Molecules Potently Inhibit Hepatitis B and D Virus Entry - (07/03/23)   RBD1016, an siRNA, Lowers HBsAg for 24 Weeks in Phase 1 Placebo Trial - Mark Mascolini (07/03/23)   The TLR8 agonist Selgantolimod modulates Kupffer cell differentiation status and indirectly impairs HBV entry into hepatocytes via an IL-6-dependent mechanism - (07/03/23)   Transcriptional analysis of HBV infected liver after treatment with Selgantolimod reveals longitudinal changes in both inflammation-related pathways and B cell receptor repertoire - (07/03/23)   Results of a Phase 1b, Open-label, Multicenter Study of Selgantolimod (GS-9688) in Special Populations of Patients With Chronic Hepatitis B - (07/03/23)   Long-term Safety Profile of Tenofovir Alafenamide in Chronic Hepatitis B Patients: Final 8-Year Results of 2 Phase 3 Studies - (07/03/23)   Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International Network (HDIN) - (07/03/23)   Resmetirom Improves the Lipid/Lipoprotein Profile in Patients With Nonalcoholic Fatty Liver Disease - (07/03/23)   Resmetirom Helps Regulate Thyroid Hormone Levels Within the Liver in Patients With Nonalcoholic Fatty Liver Disease - (07/03/23)   Resmetirom Helps Regulate Thyroid Hormone Levels Within the Liver in Patients With Nonalcoholic Fatty Liver Disease - (07/03/23)   Imaging and Biomarker Thresholds to Accurately Diagnose NASH Cirrhosis in a 180-patient Biopsy-confirmed Cohort - (07/03/23)   Artificial intelligence to measure fibrosis change on liver biopsy in MAESTRO-NASH: a Phase 3 52-week serial liver biopsy study in 966 patients with NASH treated with resmetirom or placebo - (07/03/23)   Trends in hepatitis B and hepatitis C related hepatocellular carcinoma - Increasing Cases, 2015 to 2030 - (07/02/23)   Risk of developing cancer - comparison of HBV, HCV, and smoking - (07/02/23)   Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection - (07/01/23)   Model-based meta-analysis of pegylated IFN-alpha induced HBsAg loss at end of treatment and 24 weeks post treatment in chronic hepatitis B virus infection - (06/30/23)   Hepatitis B surface antigen loss rate and safety and discontinuations with pegylated interferon alpha in chronic hepatitis B virus infection, a systematic review - (06/30/23)   Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report - (07/01/23)   The impact of removing all hepatitis B virus (HBV) testing and treatment restrictions - (06/30/23)   Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in DAA failure patients: an integrative analysis - (07/01/23)   Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV-uninfected recipients: Results from the HCV-TARGET study - (06/30/23)   Unusual HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients - (06/30/23)   Evaluating utilization and management of comedications with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir - (06/30/23)   Concomitant use of Proton Pump Inhibitors and Sofosbuvir/Velpatasvir: Evidence from Randomized Clinical Trials and Real-World Data - (06/30/23)   Achieving hepatitis C micro-eliminating in 4 female prisons through a nurse led test and treat approach of pathway optimisation and whole prison testing - (06/30/23)   HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care - (06/30/23)   HCV screening before endoscopy in hepatogastroenterology outpatient clinic: results of DEPISTC-ENDO study - (06/30/23)   Improving blood borne virus screening in immigration removal centres in the UK - (06/30/23)   AUTOMATION OF HEPATITIS C SCREENING IN THE HOSPITAL SETTING BASED ON EXTRAHEPATIC MANIFESTATIONS AND RISK PROFILE. PRELIMINARY RESULTS FROM THE HOSPITALS WITHOUT C PROGRAM (HOSPITALES SIN C) - (06/30/23)   Screening for hepatitis C virus using rapid diagnostic test (RDT) coupled with mammography in women aged from 50 to 74 years in Montpellier (France). (Mamm'OC NCT05067374) - (06/30/23)   Simple Record Review Finds 37% With HCV Who Fell Between Care Cascade Cracks - Mark Mascolini (06/30/23)   The risks of first hepatic decompensation and HCC remain constant during long-term follow-up and can be stratified by a one-time assessment after HCV-cure - (06/30/23)   A prospective, pragmatic post-authorisation safety study of early recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after direct-acting antiviral (DAA) therapy: DAA-PASS - Mark Mascolini (06/30/23)   Achieving Hepatitis C micro-elimination in 4 female prisons through a nurse led test and treat approach of pathway optimisation and whole prison testin - (06/30/23)   Liver-Derived Progenitor Cells Ease Fibrosis, Inflammation in NASH - Mark Mascolini (06/30/23)   Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN) - Mark Mascolini (06/30/23)   Fast Response to REP 2139-Mg in 3 With HDV/HBV and Decompensated Cirrhosis - Mark Mascolini (06/30/23)   HCV & HBV Summary Wrap-Up/ Lost Our Way on HCV - (06/30/23)   MAFLD is better than ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct antiviral agents - (06/30/23)   Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study - (06/30/23)   Concomitant use of Proton Pump Inhibitors and Sofosbuvir/Velpatasvir: Evidence from Randomized Clinical Trials and Real-World Data - (06/30/23)   Population Adjusted Prevalence of Hepatitis Delta Virus in 21 Countries and Territories - (06/29/23)   A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D - (06/29/23)   Lonafarnib With Ritonavir Slows HDV in 48-Week Placebo Trial - Mark Mascolini (06/29/23)   HDV Full Genome Sequencing and Sensitive HBV Genotyping from a Large Cohort of HBV/HDV Co-infected Patients - (06/29/23)   The impact of hepatitis D virus infection on health-related quality of life and fatigue in patients untreated for HDV: Descriptive results from a cross-sectional study across Italy, Germany, Spain and the US - (06/29/23)   Qualitative interviews to assess the impact of chronic hepatitis delta virus infection on health-related quality of life in untreated patients from the US, Italy, Spain, and Germany - (06/29/23)   Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection - (06/29/23)   Hepatitis Delta Treatment Utilization in the United States: An Analysis of Commercially Insured Adults With Hepatitis Delta Virus Infection - (06/29/23)   Significantly Higher Clinical and Economic Burden Following Diagnosis of Hepatitis Delta Virus Infection Among Commercially Insured Adults With Chronic Hepatitis B in the United States - (06/29/23)   Healthcare Resource Use and Costs Associated With Hepatitis Delta Virus Infection Compared With Hepatitis B Virus Monoinfection Among Commercially Insured Patients in the US - (06/29/23)   Increased Baseline Comorbidity Burden Among Commercially Insured Patients With Hepatitis Delta Virus Infection vs Hepatitis B Virus Monoinfection in the United States - (06/29/23)   Timed Calorie Cuts Beat Standard Dieting for Fibrosis, Metabolic Measures With NAFLD - Mark Mascolini (06/28/23)   Early Trials of siRNA ALN-HSD for NASH Show Safety, Drop in Target mRNA - Mark Mascolini (06/28/23)   Resmetirom Resolves NASH and Lessens Fibrosis in 52-Week Placebo Trial - Mark Mascolini (06/28/23)   FASN Inhibitor Denifanstat Improves NASH Markers in 26-Week Analysis - Mark Mascolini (06/28/23)   Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial - (06/28/23)   Pemvidutide Cuts NAFLD Liver Fat and Weight Through 24 Weeks - Mark Mascolini (06/28/23)   Efinopegdutide Cuts Liver Fat More Than Semaglutide in 24 Weeks - Mark Mascolini (06/28/23)   Resmetirom Resolves NASH and Lessens Fibrosis in 52-Week Placebo Trial - Mark Mascolini (06/28/23)   Intrahepatic Characterization of Virological and Immunological Markers in Two Distinct Populations of Chronic Hepatitis B: Baseline Assessment of Core Liver and Fine Needle Aspiration Biopsies From the Investigational INSIGHT Study - (06/28/23)   A Phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide in individuals with nonalcoholic fatty liver disease - (06/28/23)   NAFLD Efinopegutide Phase 2a/ Fatty Liver New Drugs-Public Health Research/Survey - (06/28/23)   AI To Measure Fibrosis in MAESTRO-NASH Study with Resmetirom - (06/28/23)   New Tool for Self-stigma in Chronic Hepatitis B: Content and Psychometric Validation of a New Patient-reported Outcome Instrument - (06/26/23)   Association of Post-treatment Virologic Relapse and Biochemical Flares With HBV Serum Biomarkers in Long-term Virologically Suppressed HBeAg negative Patients Stopping NA Treatment: Exploratory Analyses From the Control Arm of the REEF-2 Study - (06/26/23)   Intrahepatic Characterization of Virological and Immunological Markers in Two Distinct Populations of Chronic Hepatitis B: Baseline Assessment of Core Liver and Fine Needle Aspiration Biopsies From the Investigational INSIGHT Study - (06/26/23)   Treatment eligibility and initiation among chronic hepatitis B patients in a real-world setting in the United States - (06/26/23)   VIR-2218 and VIR-3434 Therapy Is Efficacious in Preclinical Models of Hepatitis Delta Virus Infection - (06/26/23)   Single-dose pharmacokinetics of VIR-3434, a novel neutralizing monoclonal antibody, in participants with chronic hepatitis B virus infection - (06/26/23)   siRNA VIR-2218 + Vaccinal Monoclonal Antibody VIR-3434 Phase 2 Post-Treatment Follow-up MARCH Trial - (06/26/23)   Long-term Efficacy of Tenofovir Alafenamide in HBeAg-positive and HBeAg-negative Chronic Hepatitis B Patients Treated for up to 8 Years in 2 Phase 3 Studies - (06/26/23)   Continued Treatment of Early Nonresponders or Partial Virologic Responders With Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta Through Week 96 Leads to Improvement in Virologic and Biochemical Responses - (06/26/23)   Predictors of severe flares after nucleos (t)ide analogue cessation-results of a global cohort study (RETRACT-B study) - (06/26/23)   Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial - (06/26/23)   Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: a nationwide cohort study (TDF v Entecavir) - (06/26/23)   Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis - (06/26/23)   Intrahepatic Characterization of Virological and Immunological Markers in Two Distinct Populations of Chronic Hepatitis B: Baseline Assessment of Core Liver and Fine Needle Aspiration Biopsies From the Investigational INSIGHT Study - (06/26/23)   Association of Post-treatment Virologic Relapse and Biochemical Flares With HBV Serum Biomarkers in Long-term Virologically Suppressed HBeAg negative Patients Stopping NA Treatment: Exploratory Analyses From the Control Arm of the REEF-2 Study - (06/26/23)   LOW HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT SUSTAINED RESPONSE AND HBSAG LOSS IN PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY - (06/26/23)   Intrahepatic Characterization of Virological and Immunological Markers in Two Distinct Populations of Chronic Hepatitis B: Baseline Assessment of Core Liver and Fine Needle Aspiration Biopsies From the Investigational INSIGHT Study - (06/26/23)   Treatment With siRNA JNJ-73763989 Plus Nucleos(t)ide Analogue (NA) Decreases HBsAg and HDV RNA Levels in Patients With Chronic Hepatitis D (CHD): Part 1 of the REEF-D Study - (06/26/23)   Comparable Risk of Cardiovascular Events in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide - (06/26/23)   Increased Baseline Comorbidity Burden Among Commercially Insured Patients With Hepatitis Delta Virus Infection vs Hepatitis B Virus Monoinfection in the United States - (06/26/23)   A Retrospective Observational Cohort Study of Liver-Related Events Among Patients With Hepatitis B Virus Infection With and Without Hepatitis Delta Virus Infection - (06/26/23)   Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta - (06/26/23)   HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. - Mark Mascolini (06/26/23)   HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort - (06/26/23)   Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study - (06/26/23)   Patients With Chronic Hepatitis Delta Virus Infection Have Higher Risk of Disease Progression Than Chronic Hepatitis B Virus Monoinfection-Results From a Spanish National Hospital Database - (06/26/23)   Stopping Bulevirtide After Long-Term HDV Control Appears Safe With Close Monitoring - Mark Mascolini (06/26/23)   SIGNIFICANT IMPROVEMENT OF NON-INVASIVE FIBROSIS TESTS IN HDV COMPENSATED CIRRHOTIC PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION TREATED WITH BLV MONOTHERAPY UP TO 96 WEEKS - (06/26/23)   VIROLOGICAL AND CLINICAL OUTCOMES OF PATIENTS WITH HDV-RELATED COMPENSATED CIRRHOSIS TREATED WITH BULEVIRTIDE MONOTHERAPY: THE RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D) - (06/26/23)   Study of hepatitis delta virus replication markers in anti-HBc positive patients with chronic hepatitis C - (06/26/23)   Final results of a hepatitis C micro-elimination campaign in a highly endemic, well-defined demographic area of peri-urban Karachi, Pakistan. - (06/26/23)   Estimating the Economic Value Allocation of the Social Surplus Generated by the Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015-2019 - (06/26/23)   CHALLENGES AND STRATEGIES TO IMPROVE LINKAGE TO CARE AND TREATMENT FOR HEPATITIS C IN PREGNANCY: PERSPECTIVES FROM A GLOBAL COMMUNITY OF PRACTICE - (06/26/23)   Care cascade for perinatal HCV and implications of early RNA testing (46% tested)a - (06/26/23)   Achieving a Hepatitis C cure in those with hepatocellular carcinoma is associated with an improvement in overall survival: Real world data - (06/26/23)   HCV Screening Rates in Reproductive Age Women After Universal Screening Guidelines - (06/26/23)   Most vulnerable HCV patient groups (PWID) treated with direct acting antivirals achieve high response rates and gain quality of life - Data from the German Hepatitis C-Registry (DHC-R) - (06/26/23)   HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network - (06/26/23)   The prevalence of hepatitis C virus infection in high-risk patients with high normal alanine aminotransferase (ALT) in Israel: A bio bank analysis - (06/26/23)   The Impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry - (06/26/23)   Same Day Test, treat and cure patients with CHC undergoing opioid agonist substitution therapy at Drug Addiction Center - (06/26/23)   Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States - (06/26/23)   Real-life effectiveness of VOX/SOF/VEL in hepatitis C patients previously treated with SOF/VEL or GLE/PIB - (06/26/23)   Sofosbuvir/ Velpatasvir/ Voxilaprevir for DAA-experienced HCV Patients: A Systematic Review and Meta-Analysis - (06/26/23)   Sofosbuvir/Velpatasvir (S/V) For The Treatment Of HCV Infection Among Vulnerable Inner-city (PWID) Residents: Extending The Results Of Clinical Trial Part 2 - (06/26/23)   Cascade of care and HCV treatment of inner city (PWID) populations engaged in care through community pop-up clinics (CPCs) SVR 97% - (06/26/23)   Sofosbuvir/Velpatasvir (S/V) For The Treatment Of HCV Infection Among Vulnerable Inner-city (PWID) Residents: Extending The Results Of Clinical Trial Part 2 - (06/26/23)   Real-world Data on Long-term Quality Of Life After Glecaprevir/Pibrentasvir Therapy: Data From the German Hepatitis C Registry (DHC-R) - (06/26/23)   Results of the hepatitis B and C screening within the "Check-Up35+" in the German primary care setting one year after implementation by the Federal Joint Committee - (06/26/23)   Real-world Data on Long-term Quality Of Life After Glecaprevir/Pibrentasvir Therapy: Data From the German Hepatitis C Registry (DHC-R) - (06/26/23)   Viral hepatitis C: Therapy and resistance Retreatment of patients experiencing failure with Hepatitis C direct-acting antivirals. Sof/Vel/Vox, G/P+Sof - (06/26/23)   Predictors of long-term mortality after HCV eradication among PLWH - (06/26/23)   HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network - (06/26/23)   Smoking and obesity promote systemic inflammation in patients with compensated and decompensated cirrhosis - (06/25/23)   Effects of Nutritional Therapy on Sarcopenia in Patients with Liver Cirrhosis - A Randomized Controlled Trial - (06/25/23)